CurrentBlue Cross Blue Shield - TexasPolicy CPCPLAB019

Thyroid Disease Testing

Defines plan lab management reimbursement criteria for thyroid function and antibody testing, specifying clinical indications, monitoring intervals, reimbursable vs non-reimbursable tests, and a procedure code list. Applies to Blue Cross Blue Shield of Texas products with plan-specific applicability.

Policy Summary

PayerBlue Cross Blue Shield - Texas

PolicyThyroid Disease Testing

Policy CodePolicy CPCPLAB019

Change TypeRevisions and additions to indications, monitoring, antibodies, and codes

Effective DateAug 8, 2025

Next Review Date

Key ActionProviders must submit accurate documentation of signs/symptoms, diagnosis, treatment changes, pregnancy status, IRT status, hypothalamic-pituitary disease, or cancer surveillance to support reimbursement for thyroid testing.

SourceLink

POLICY UPDATE CHANGES

Removed 'are undergoing evaluation for infertility' from prior language and adjusted #1.d to 'TSH testing for individuals capable of becoming pregnant who have experienced two or more pregnancy losses.'

Added #1.e: 'TSH testing for individuals with a thyroid nodule.'

Reformatted and specified thyroid antibodies in #4 to 'Tg-Ab, TPOAb, TRAB, thyroid-stimulating immunoglobulins [TSI]' with testing once every three years.

Clarified central/secondary hypothyroidism monitoring and added fT4 monitoring for secondary hypothyroidism every 6 weeks upon dose change and annually in stable individuals.

Clarified that TSH is the appropriate screening test for asymptomatic individuals on drugs that interfere with thyroid function and specified intervals (annually, on medication/dose change, if symptoms).

Added code 83520 to procedure codes list.

MultipleCovered Indications

6Excluded Tests

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Procedure codes listed

Policy Overview

Policy CPCPLAB019 (Thyroid Disease Testing) is CURRENT and defines plan lab management reimbursement criteria for thyroid function and antibody testing. Approval date is April 28, 2025 with a plan effective date of August 8, 2025. The policy summarizes reimbursable indications, monitoring intervals, non-reimbursable tests, and a procedure code list.

The Plan notes that not all requirements apply to each product and that plan documents govern applicability; if a conflict arises between this policy and plan documents the plan document will govern, and if a conflict arises with a provider contract the provider contract will govern. Providers must use standard HIPAA-approved code sets, submit accurate clinical documentation upon request, and may be asked for additional documentation to support reimbursement.

Policy facts as key header

Policy NumberCPCPLAB019

PayerBlue Cross Blue Shield - Texas

Policy TitleThyroid disease laboratory testing reimbursement

Policy CodeCPCPLAB019

StatusCURRENT

Effective Date2025-08-08

Last Review2025-04-28

Next Review

Reimbursable Indications & Clinical Criteria

Reimbursable Thyroid Function Testing

Thyroid function testing may be reimbursable in the following situations:

ALL of the following

1.a Hypothyroidism
- TSH to confirm or rule out primary hypothyroidism
- Free T4 (fT4) testing as a follow up to abnormal TSH findings
- TSH and fT4 testing in cases of suspected secondary (central) hypothyroidism
- Monitoring - primary hypothyroidism: For individuals being treated for primary hypothyroidism, monitoring with TSH and fT4 testing every 6 weeks upon dosage change and annually in stable individuals

Procedure Codes

Procedure Codes (listed; inclusion does not guarantee coverage)mixed

80438
80439
83519
83520
84432
84436
84439
84442
84443
84445

1–10 of 16

1/2

Billing Rule

Code usage and claims submission

Submit claims using valid HIPAA-approved code sets. Inclusion of codes listed in the policy does not guarantee reimbursement; claims remain subject to plan documents, medical policies, provider contracts, and claim edit protocols.

Codes listed: 80438, 80439, 83519, 83520, 84432, 84436, 84439, 84442, 84443, 84445, 84479, 84480, 84481, 84482, 86376, 86800
Claims are subject to plan documents, provider contracts, medical policies, and claim edit protocols
Providers must submit claims using valid HIPAA-approved code sets and may be asked to provide additional documentation upon request

Billing, Documentation & Prior Authorization Guidance

Documentation Required

Clinical indication documentation

Provide clinical documentation to support thyroid testing requests. Required examples of documentation include signs/symptoms, diagnosis, treatment changes, pregnancy status, IRT status, hypothalamic-pituitary disease, and cancer surveillance.

Signs and symptoms consistent with hypothyroidism or hyperthyroidism (see policy notes for examples)
Diagnoses supporting testing (e.g., hypothyroidism, hyperthyroidism, thyroid cancer)
Treatment changes or monitoring needs (dose changes, ongoing therapy)
Pregnancy or postpartum status
Immune reconstitution therapy (IRT) status
Hypothalamic-pituitary disease monitoring needs
Cancer surveillance (serum thyroglobulin and/or Tg‑Ab testing)

Monitoring Intervals & Frequency Thresholds

Reimbursable monitoring thresholds

Monitoring interval - primary hypothyroidism after dose changeevery 6 weeks

Monitoring interval - secondary hypothyroidism after dose changeevery 6 weeks (fT4)

Monitoring interval - hyperthyroidism treatment follow-upevery 8 weeks (TSH and fT4)

TSH testing frequency during pregnancy/postpartum with symptomsonce every 4 weeks

IRT monitoring frequencyonce every 3 months (TSH) with reflex fT4 and fT3 if abnormal

Thyroid antibody testing frequencyonce every three years

Key Definitions

Definitions

IRTImmune reconstitution therapy (examples: alemtuzumab for MS, HAART for HIV, post-allogeneic BMT/HSCT)

fT4Free thyroxine

TSHThyroid stimulating hormone

Tg-AbAntithyroglobulin antibody

TPO-AbAntithyroid peroxidase antibody

TRABThyrotropin receptor antibodies

TSIThyroid-stimulating immunoglobulins

Background and Evidence Sources

Background: The Plan implements specific laboratory-management reimbursement criteria for thyroid disease testing that reference current clinical guidelines and the medical literature. Reimbursement criteria include indications and monitoring intervals for hypothyroidism, hyperthyroidism, drug-induced risk, pregnancy/postpartum testing, immune reconstitution therapy monitoring, hypothalamic-pituitary disease, thyroid nodules, antibody testing, and surveillance testing for thyroid cancer. Providers must code using standard code sets and may be asked to provide documentation of symptoms, diagnoses, treatment changes, pregnancy/IRT status, or cancer surveillance to support reimbursement.

Evidence: Literature update performed (document updated with literature review on 04/28/2025); guidelines cited include the American Thyroid Association (ATA), American Association of Clinical Endocrinologists (AACE), American College of Obstetricians and Gynecologists (ACOG), UpToDate, and the European Thyroid Association.

Policy Revision History

04/28/2025material_changeLatest

Added #1.e: 'TSH testing for individuals with a thyroid nodule.'

04/28/2025

Policy Summary

PayerBlue Cross Blue Shield - Texas

PolicyThyroid Disease Testing

Policy CodePolicy CPCPLAB019

Change TypeRevisions and additions to indications, monitoring, antibodies, and codes

Effective DateAug 8, 2025

Next Review Date

SourceLink

On This Page

every 6 weeks; annually in stable individuals

Monitoring - secondary hypothyroidism: For individuals being treated for secondary hypothyroidism, monitoring with fT4 testing every 6 weeks upon dosage change and annually in stable individualsevery 6 weeks (fT4); annually in stable individuals

1.b Hyperthyroidism

TSH testing to confirm or rule out overt hyperthyroidism
Free T4 testing as a follow up to abnormal TSH findings
Total T3 (TT3) or free T3 (fT3) testing to confirm a diagnosis of hyperthyroidism
Free T4 testing to distinguish between overt and subclinical hyperthyroidism
Monitoring after treatment: In patients being treated for hyperthyroidism, repeat testing of TSH and fT4 should occur every 8 weeks; annual monitoring after the first year even if asymptomatic for risk of relapse or late-onset hypothyroidismevery 8 weeks; annual thereafter

1.c Drug-induced risk (asymptomatic individuals on interfering drugs)

Annuallyannually
When dosage or medication changeson medication/dose change
If symptoms consistent with thyroid dysfunction developas needed with symptoms

1.d Recurrent pregnancy loss: TSH testing for individuals capable of becoming pregnant who have experienced two or more pregnancy losses

1.e Thyroid nodule: TSH testing for individuals with a thyroid nodule

1.f One-time TSH screening (selected high-risk or pediatric groups)

Asymptomatic individuals at high risk due to personal or family history of thyroid dysfunctionone-time
Asymptomatic individuals at high risk due to personal or family history of type 1 diabetes or other autoimmune diseaseone-time
Individuals with disease or neoplasm of the thyroid or other endocrine glandsone-time
Individuals with chronic or acute urticariaone-time
Pediatric individuals diagnosed with short statureone-time
Pediatric individuals with a clinical finding of failure-to-thriveone-time

1.g IRT monitoring: TSH testing once every 3 months, with reflex fT4 and fT3 when TSH is abnormal, for individuals undergoing immune reconstitution therapy (IRT)once every 3 months (TSH) with reflex fT4 and fT3 if abnormal

Includes alemtuzumab for MS, HAART for HIV, and post-allogeneic BMT/HSCT

1.h Hypothalamic-pituitary disease monitoring: Monitoring of TSH and fT4 biannually for individuals less than 18 years of age; annually for individuals 18 years of age or olderbiannually (<18); annually (>=18)

1.i Primary mitochondrial disease: Annual screening of TSH and fT4 for individuals diagnosed with primary mitochondrial diseaseannually

Pregnancy and Postpartum Testing

Reimbursable testing intervals for pregnant or postpartum individuals with symptoms or diagnosed disease:

ANY of the following

Symptoms: For pregnant or postpartum individuals with symptoms of thyroid dysfunction, TSH and fT4 testing once every 4 weeks may be reimbursableonce every 4 weeks
Testing should be performed at labs with trimester-specific normal ranges; fT4 preferred; TT4 may be useful if discordant or trimester ranges unavailable
Diagnosed hyperthyroidism in pregnancy/postpartum: For pregnant or postpartum individuals diagnosed with hyperthyroidism, TT4, TgAb, TRab, and TPOAb may be reimbursable
See Note 3 re: trimester-specific labs and preferred assays

Reimbursable Thyroid Antibody and Tumor Marker Testing

Frequency and indications for antibody and thyroglobulin testing:

ANY of the following

Antibodies for hypo/hyperthyroidism: For individuals with hypothyroidism or hyperthyroidism, testing once every three years for thyroid antibodies may be reimbursableonce every three years
Specified antibodies: Tg-Ab, TPO-Ab, TRAB, thyroid-stimulating immunoglobulins (TSI)
Thyroid cancer surveillance: For individuals with thyroid cancer, testing for serum thyroglobulin and/or Tg-Ab levels for detection of tumor recurrence, post-surgical evaluation, surveillance, and maintenance for differentiated thyroid carcinomas may be reimbursable

Not Reimbursable Tests

Tests not reimbursable for evaluation of thyroid dysfunction or as stated:

ANY of the following

Thyrotropin-releasing hormone (TRH) testing is not reimbursable for evaluation of cause of hyperthyroidism or hypothyroidism
Thyroxine-binding globulin (TBG) testing is not reimbursable for evaluation of cause of hyperthyroidism or hypothyroidism
Reverse T3, T3 uptake and total T4 testing are not reimbursable for other situations not mentioned above
Measurement of total T3 (TT3) and/or free T3 (fT3) is not reimbursable to assess hypothyroidism
Measurement of total or free T3 level is not reimbursable to assess levothyroxine dose in hypothyroid individuals
Testing for thyroid dysfunction during a general exam in asymptomatic nonpregnant individuals without abnormal findings is not reimbursable

Denial Risk

Non-reimbursable tests risk

Claims for certain tests may be denied as not reimbursable. Examples of tests at risk for denial include TRH and TBG testing, reverse T3, T3 uptake, total T4 in contexts not specified as reimbursable, TT3/fT3 to assess hypothyroidism or levothyroxine dosing, and routine asymptomatic screening in nonpregnant individuals without abnormal findings.

Thyrotropin-releasing hormone (TRH) testing
Thyroxine-binding globulin (TBG) testing
Reverse T3
T3 uptake
Total T4 (when not specified as reimbursable)
Total or free T3 (TT3/fT3) to assess hypothyroidism or to adjust levothyroxine dose
Routine thyroid screening during a general exam in asymptomatic nonpregnant individuals without abnormal findings

Prior Authorization

Plan-specific applicability

Not all requirements in this policy apply to every product. Plan documents and provider contracts govern coverage and applicability. Providers should review applicable plan documents to determine eligible coverage for services rendered.

Plan documents (e.g., Certificates of Benefits, benefit booklets, Summary Plan Descriptions) govern when conflicts exist
Blue Cross and Blue Shield of Texas may use reasonable discretion in applying the policy but plan terms and provider contracts prevail
Review member-specific plan documents to confirm applicability before submitting authorization requests or claims

Reformatted and specified thyroid antibodies in #4 to 'Tg-Ab, TPOAb, TRAB, thyroid-stimulating immunoglobulins [TSI]' with testing once every three years.

02/05/2025material_change

Clarified central/secondary hypothyroidism monitoring and added fT4 monitoring for secondary hypothyroidism every 6 weeks upon dose change and annually in stable individuals.

02/05/2025material_change

Clarified that TSH is the appropriate screening test for asymptomatic individuals on drugs that interfere with thyroid function and specified intervals: annually, on medication/dose change, and if symptoms develop.

02/05/2025non_material_change

Added code 83520 to procedure codes list.